Fig. 7: Model of microbiota-mediated protection against influenza virus infection.
From: Gut microbiota-derived isovaleric acid ameliorates influenza virus infection via gut-lung axis
H9N2 infection induces distinct alterations in gut microbial communities, characterized by progressive depletion of Prevotella species with increasing infection severity. P. copri supplementation not only attenuates H9N2 infection but also restructures the gut microbiota composition and SCFA metabolite profiles. Notably, isovaleric acid supplementation mitigates H9N2/N1N1 infection.
